Physician profile
Robert B Harris
NPI 1548219231
$3,393.46
in general payments reported to CMS, 2019-2025
36 companies · $545 in 2025
The $545 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $394 · 2021: $294 · 2022: $417 · 2023: $859 · 2024: $636 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,996 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,995.59 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $685.62 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $586.16 | 2020-2025 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $314.75 | 2022-2024 | |
| Lilly USA, LLC | $238.73 | 2020-2025 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $169.52 | 2019-2025 | |
| Novo Nordisk INC | $144.57 | 2019-2022 | |
| Glaxosmithkline, LLC. | $142.58 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $110.91 | 2022-2024 | Nuzyra |
| Avanir Pharmaceuticals, INC. | $107.09 | 2019-2022 | |
| Amgen INC. | $94.80 | 2020-2025 | Repatha, Otezla, Otezla |
| Melinta Therapeutics, LLC | $88.65 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.92 | 2019-2023 | |
| Axsome Therapeutics, INC. | $57.36 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $51.82 | 2020-2023 | Trintellix |
| Insulet Corporation | $51.19 | 2024-2025 | Omnipod |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.